"Per and Michael's arrivals come as we're accelerating our capital markets services to meet client demand. The second half of 2020 was the most active six months for the tech and life sciences IPO space since Fenwick began tracking the data in 2012, and the market appears poised for a post-pandemic boom. As clients pursue more alternatives to access capital markets, whether through IPOs, direct listings or through a merger with a SPAC, it creates a very dynamic playing field for our capital markets team." – Alan Smith, Fenwick corporate practice chair
We are happy to share the news that Per Chilstrom and Michael Pilo are joining the firm as capital markets partners in our New York office.
Per and Michael bring extensive experience representing technology and life sciences companies and investment banks in a full range of capital markets transactions and public company matters.
Per advises large corporate and financial institutions on matters involving U.S. and cross-border capital markets services. He counsels issuers and underwriters in connection with both public and private offerings of equity and debt securities—including high-yield and convertible bonds—and transactions involving special purpose acquisition companies (SPACs).
Michael also represents issuers and investment banks in public and private capital markets deals, such as initial public offerings, high-yield bond offerings, private placements of equity and debt securities, and specialty finance transactions involving SPACs. He regularly advises clients on securities law compliance, corporate governance practices and disclosure obligations.
Fenwick's Capital Markets & Public Companies team is routinely involved in some of the most high-profile IPOs and other equity offerings for the technology and life sciences industries. The team has been named Capital Markets Group of the Year by Law360 and is listed among California's leading firms for capital markets in Chambers USA.
Fenwick released its semi-annual report and analysis of the IPO landscape based on a survey of 366 executives and investors in the technology and life sciences sectors conducted in January 2021. The findings—from 2020 milestones to the 2021 outlook—are shared in the custom report: IPO Landscape: Surging SPACs and a Pandemic Boom Ahead.